Allergan Aesthetics Brings Nine Abstracts, GLP-1 Data to ASDS 2026
Image
Irvine, California – November 03, 2026 -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego, including new data from two Phase 4 studies on aesthetic treatment in patients taking GLP-1-related medications for weight management.
Two Phase 4 studies track satisfaction and psychosocial outcomes after medical weight loss
Both studies will be shown as video oral abstracts and examine facial appearance, skin quality, patient satisfaction and psychosocial outcomes. One evaluates multimodal aesthetic treatment in a medical weight loss cohort (HARMONY IN DIVERSITY). The other assesses hyaluronic acid injectables in the same patient group.